research UP-02.010 Urinary PSA: Marker of Benign Prostatic Hyperplasia?
Urinary PSA could be an early marker for enlarged prostate.
Search
for
Sort by
Research
300-330 / 1000+ results 
research Modelling of the composition of emulsion medicines and cosmetics stabilized by a biocomplex of surfactant substances based on rhamnolipids Pseudomonas sp. PS-17
A semi-automated system can effectively help choose emulsion ingredients, simplifying the creation of medicinal and cosmetic products.
research FINASTERIDE AND PSA
research Atherogenesis: Estrogen Induction of Polysialylated nCAM (PSA-nCAM) Blocks Monocyte Capture by Vascular Endothelial Cells
Estrogen helps prevent artery plaque by stopping monocyte capture in blood vessels.
research 42134 Long-term Efficacy of Guselkumab (GUS) on Fatigue and Identification of Early Treatment Targets: Post Hoc Analysis Through 2 Years of a Phase 3, Randomized, Double-blind, Placebo-controlled Study in Biologic-naïve Patients With Psoriatic Arthritis (PsA)
Guselkumab effectively reduces fatigue in Psoriatic Arthritis patients over two years.
research Urinary Retention in Patients with BPH Treated with Finasteride or Placebo over 4 Years
Finasteride lowers risk of urinary issues and surgery by over 50% in 4 years.
research Liarozole—a novel treatment approach for advanced prostate cancer: results of a large randomized trial versus cyproterone acetate
Liarozole may be more effective than cyproterone acetate for treating advanced prostate cancer, with better PSA response and survival rates, while maintaining quality of life.
research 5-α-Reductase inhibitors for prostate cancer chemoprevention: an updated Cochrane systematic review
5-α-reductase inhibitors reduce prostate cancer risk but may cause sexual dysfunction and don't affect high-grade tumor or death rates.
research Efficacy and Side Effects of Drugs Commonly Used for the Treatment of Lower Urinary Tract Symptoms Associated With Benign Prostatic Hyperplasia
Different drugs for prostate-related urinary symptoms work but have various side effects, and treatment should be tailored to the individual.
research Finasteride-its impact on sexual function and prostate cancer
Finasteride reduces prostate cancer risk but may affect ejaculatory volume and requires careful consideration for young men.
research Prevalence of metabolic syndrome and its components among men with and without clinical benign prostatic hyperplasia: a large, cross-sectional, UK epidemiological study
Men with benign prostatic hyperplasia are more likely to have metabolic syndrome than those without it.
research Dutasteride for the treatment of benign prostatic hyperplasia
Dutasteride effectively treats benign prostatic hyperplasia but isn't approved for preventing prostate cancer.
research Primary Scarring Alopecia: Clinical-Pathological Review of 72 Cases and Review of the Literature
The conclusion is that primary scarring alopecia is a complex condition that requires early and accurate diagnosis for effective treatment.
research Medikamentöse Therapie des benignen Prostatasyndroms
Combining medications is more effective for treating benign prostatic syndrome symptoms.
research Efficacy and safety of 5 alpha-reductase inhibitor monotherapy in patients with benign prostatic hyperplasia: A meta-analysis
5 alpha-reductase inhibitors can slightly improve symptoms of enlarged prostate but have a high risk of sexual side effects.
research Benign prostatic hyperplasia and male lower urinary symptoms: A guide for family physicians
Family doctors can manage older men with urinary symptoms using exams, tests, and medications.
research Value of hormonal levels in patients with male androgenetic alopecia treated with finasteride: better response in patients under 26 years old
Finasteride works better for hair loss in patients 26 or younger.
research 5-Alpha-Reductase Inhibitors and Combination Therapy
Finasteride and dutasteride are effective for long-term treatment of enlarged prostates but have sexual side effects and a risk of high-grade prostate cancer.
research Finasterida: Diez Años De Uso Clínico. Revisión Sistemática De La Literatura
Finasteride effectively reduces symptoms of enlarged prostate with minimal side effects.
research Association between prostate‐specific antigen and serum testosterone: A systematic review and meta‐analysis
Testosterone replacement therapy, especially intramuscular, raises PSA levels, but no overall link between PSA and testosterone was found except in non-BPH patients.
research Economic Issues in the Treatment of BPH
Combination therapy for BPH is cost-effective, especially for men with larger prostates.
research Estudio de patrones de implantación pilosa frontal en la mujer española caucásica
Most white Spanish women have a widow's peak, and their hairline measurements could help in hair restoration surgery.
research Alcohol and Prostate Cancer: Time to Draw Conclusions
Drinking a lot of alcohol increases the risk of prostate cancer and can worsen the condition.
research Preventive and Therapeutic Efficacy of Finasteride and Dutasteride in TRAMP Mice
Dutasteride works better than finasteride for preventing and treating prostate cancer.
research THERAPEUTIC HOTLINE: Treatment of androgenic alopecia with finasteride may result in a high grade prostate cancer in patients: fact or fiction?
Finasteride for hair loss is safe and does not increase the risk of high-grade prostate cancer.
research 5-Alpha Reductase Inhibitors in Prostate Cancer: From Clinical Trials to Clinical Practice
5-Alpha reductase inhibitors may prevent prostate cancer but are not widely used due to concerns about trial relevance and potential risks, and more research is needed to confirm long-term benefits.
research The five-year effects of testosterone replacement therapy on lipid profile and glucose tolerance among hypogonadal men in Japan: a case control study
Testosterone replacement therapy improved blood sugar and fat levels without raising prostate cancer risk in Japanese men with low testosterone.
research Three Considerations Before Advising 5-α-Reductase Inhibitors for Chemoprevention
5-α-reductase inhibitors don't prevent prostate cancer but may reduce unnecessary biopsies.
research Prostate cancer update: 2007
2007 research improved understanding of prostate cancer risk, diagnosis, and treatment, but also showed the need for personalized treatment and further study on certain therapies' risks.
research Inhibitory effects of TripTripterygium wilfordii multiglycoside on benign prostatic hyperplasia in rats
Tripterygium wilfordii multiglycoside effectively reduced prostate enlargement in rats without harmful effects.